All In Biotech

Drug Trial Radar · NCT03471351

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL

Last checked: Nov 19, 2026Latest source record: Dec 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

2

Actual

Start

Jul 18, 2018

Primary completion

Feb 13, 2019

Study completion Feb 13, 2019

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Mar 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.

Conditions

  • Classical Hodgkin Lymphoma

Interventions

  • TenalisibDrug

    Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W

  • PembrolizumabBiological

    Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHLTime frame: 21 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois

  • Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute,

    Detroit, Michigan

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.